Table 1.
Characteristics and outcomes amongst those with and without Progressive AKI
| Variable | Total (n=92) | Non-progress (n=69) | Progress (n=23) | p value |
|---|---|---|---|---|
| Age (years), mean (SE) | 64.2 (1.53) | 63.7 (1.90) | 66.0(2.21) | 0.82 |
| Gender (male), n (%) | 59 (64.1) | 43 (62.3) | 16 (69.6) | 0.53 |
| Race, n (%) | 0.70 | |||
| African American | 42 (45.7) | 32 (46.4) | 10 (43.5) | |
| Caucasian | 41 (44.6) | 29 (42.0) | 12 (52.2) | |
| Native | 1 (1.1) | 1 (1.6) | 0 (0.00) | |
| Other | 8 (8.7) | 7 (10.1) | 1 (4.4) | |
| Type of ICU admission, n (%) | ||||
| Medical | 48 (52.2) | 33 (47.8) | 15 (65.2) | 0.92 |
| Surgical | 16 (17.4) | 12 (17.4) | 4 (17.4) | 1.0 |
| Cardiovascular Surgical | 15 16.3) | 11 (15.9) | 4 (17.4) | 0.99 |
| Other | 13 (14.1) | 13 (18.8) | 0 | <0.001 |
| Comorbidities, n (%) | ||||
| CKD | 21 (22.8) | 14 (20.3) | 7 (30.4) | 0.32 |
| HTN | 60 (65.2) | 47 (68.1) | 13 (56.5) | 0.31 |
| CHF | 32 (34.8) | 22 (31.9) | 10 (43.5) | 0.31 |
| DM | 39 (42.4) | 28 (40.6) | 11 (47.8) | 0.54 |
| Nephrotoxic exposure, n (%) | ||||
| NSAIDs | 10 (10.9) | 7 (10.1) | 3 (13.0) | 0.70 |
| Aminoglycosides | 2 (2.2) | 1 (1.5) | 1 (4.4) | 0.41 |
| Amphotericin | 1 (1.1) | 1 (1.5) | 0 (0.00) | 0.56 |
| Contrast | 19 (20.7) | 16 (23.2) | 3 (13.0) | 0.30 |
| Post-cardiac Surgery | 14 (15.2) | 10 (14.5) | 4 (17.4) | 0.74 |
| Sepsis | 22 (23.9) | 17 (24.6) | 5 (21.7) | 0.78 |
| Clinical Data, mean (SE) | ||||
| Baseline eGFR (mL/min) | 65.13 (3.03) | 67.9 (3.66) | 56.83 (4.79) | 0.14 |
| Serum Creatinine (mg/dL) | 1.23 (0.05) | 1.22 (0.06) | 1.27 (0.08) | 0.33 |
| Baseline UFR (ml/hr) | 72.78 (6.4) | 80.06 (7.75) | 50.95 (9.54) | 0.03 |
| Furosemide-naïve, n (%) | 41 (44.6) | 32 (46.4) | 9 (39.1) | 0.5 |
| SOFA | 1.52 (0.14) | 1.44 (0.16) | 1.75 (0.33) | 0.58 |
| APACHE II score | 19.68 (0.89) | 18.88 (1.03) | 22.09 (1.71) | 0.10 |
| AKI stage at enrollment, n (%) | 0.89 | |||
| AKIN I | 69 (75.0) | 52 (75.4) | 17 (73.9) | |
| AKIN II | 23 (25.0) | 17 (24.6) | 6 (26.1) | |
| Primary Outcomes, n (%) | ||||
| AKIN III | 23 (25.0) | 0 (0.00) | 23 (100.0) | <.0001 |
| RRT | 10 (10.9) | 0 (0.00) | 10 (43.5) | <.0001 |
| Death | 16 (17.4) | 9 (13.0) | 7 (30.4) | 0.06 |
| AKIN III/Death | 32 (34.8) | 9 (13.0) | 23 (100.0) | <.0001 |
| Secondary Outcomes, days (SE) | ||||
| Length of ICU stay | 9.15 (1.45) | 7.81 (1.6) | 13.17 (3.13) | 0.03 |
| Length of Hospital stay | 17.29 (2.4) | 16.65 (2.97) | 19.22 (3.59) | 0.09 |
Table 1. Patient characteristics for our cohort, non-progressors and progressors are depicted above. CKD – chronic kidney disease; HTN – hypertension; CHF – congestive heart failure; DM – diabetes mellitus; eGFR – estimated glomerular filtration rate; UFR – urine flow rate; SOFA – sequential organ failure assessment; APACHE – acute physiology. P-values for categorical (continuous) variables were from Chi-square (non-parametric Kruskal-Wallis) test.